• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


News you can use

“Comorbidity of chronic pain and mood disorders: breaking the vicious cycle” This is the aim of HaPpY and we are thrilled to have been invited to join as well-known experts in this therapeutic area. HaPpY has assembled a world-class team of behavioural neuroscientists, electrophysiologists, molecular biologists, neuropharmacologists and clinicians specialising in pain and/or mood disorders from academic research labs and hospitals along with experts of the non-academic sector specialising in new instrumentation and technology, drug development and scientific promotion and communication. We can’t wait to get started. For details of all our pain and mood disorders preclinical areas please see our pain pages https://www.transpharmation.co.uk/services/


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design